EUROPEAN HEMATOLOGY ASSOCIATION

Their core work

The European Hematology Association (EHA) is a Netherlands-based professional medical society representing hematologists across Europe. In H2020, they contribute patient data infrastructure, clinical expertise, and professional network access to large-scale research initiatives targeting blood cancers and blood disorders. Their role centers on enabling big data platforms for real-world patient outcomes in hematological malignancies — leukemia, lymphoma, myeloma, and myelodysplastic syndromes — and more recently on accelerating access to advanced cell therapies like CAR-T and TCR-engineered treatments.

What they specialise in

How they've shifted over time

EHA's early H2020 work (2015-2019) centered on cataloguing hematological malignancies and building big data platforms to capture real-life patient outcomes across cancer subtypes like leukemia, lymphoma, and myeloma. From 2020 onward, their focus shifted toward translational medicine, digital health outcomes, molecular genetics, and advanced cell therapies (CAR-T, TCR engineering). This evolution tracks the broader field's move from observational data collection toward precision interventions and therapy access.

EHA is moving from data aggregation toward enabling advanced therapy development and access, making them increasingly relevant for partners working on ATMPs and personalized cancer treatment.

How they like to work

EHA operates exclusively as a participant or partner — never as coordinator — which is typical for a professional association that provides domain expertise, clinical networks, and data access rather than leading research execution. With 84 unique partners across 16 countries from just 4 projects, they work in very large consortia (averaging 20+ partners per project). This makes them a network hub: partnering with EHA gives access to a wide web of hematology-focused clinical and research organizations across Europe.

EHA has collaborated with 84 unique partners across 16 countries through just 4 projects, indicating participation in major pan-European consortia. Their network spans clinical centers, pharmaceutical companies, and research institutions focused on hematology and oncology.

What sets them apart

EHA is not a research lab — it is the professional association for European hematologists, giving it unmatched reach into the clinical hematology community. This means they bring something no university or company can: organized access to practicing clinicians, patient registries, and professional consensus across Europe. For any consortium working on blood disorders or advanced therapies in hematology, EHA provides legitimacy, clinical network access, and the ability to translate research into practice guidelines.

Highlights from their portfolio

• HARMONY
  Flagship big data initiative in hematology with EUR 831,750 in EC funding, building a Europe-wide platform for real-world patient data across multiple blood cancer types.
• T2EVOLVE
  Positions EHA at the frontier of CAR-T and TCR cell therapy development, directly addressing the regulatory and manufacturing barriers to advanced therapy access.
• HARMONY PLUS
  Continuation and expansion of HARMONY with EUR 664,250, adding molecular genetics, business model development, and digital health outcome dimensions.